natgillin/translations-raw huggingface dataset:
Reversal of neutropenia or maintaining normal neutrophil counts: filgrastim should be given by subcutaneous injection.
Promjena u liječenju neutropenije ili održavanju normanlne razine neutrofila: filgrastim treba davati supkutanom injekcijom.
Reversal of neutropenia or maintaining normal neutrophil counts: Grastofil should be given by subcutaneous injection.
Obrat nutropenije ili održavanje normalnog broja neutrofila: Grastofil se trebaprimijeniti putem supkutane injekcije.
REVERSE
POLEĐINA
Reverse genetic experiments showed that the presence of 6 mutations in the protease (I13V, V32I, L33F, K45I, V82L, I84V) was required to confer > 10-fold resistance to tipranavir while the full 10-mutation genotype conferred 69-fold resistance to tipranavir.
Reverzni genetski eksperimenti pokazuju da je potrebno prisustvo 6 mutacija u proteazi (I13V, V32I, L33F, K45I, V82L, I84V) za postizanje > 10-struke rezistencije na tipranavir, dok je potpuni 10- mutacijski genotip imao 69-struku rezistenciju na tipranavir.
Reverse genetic experiments showed that the presence of 6 mutations in the protease (I13V, V32I, L33F, K45I, V82L, I84V) was required to confer > 10-fold resistance to tipranavir while the full 10-mutation genotype conferred 69-fold resistance to tipranavir.
Reverzni genetski eksperimenti pokazuju da je potrebno prisustvo 6 mutacija u proteazi (I13V, V32I, L33F, K45I, V82L, I84V) za postizanje > 10-struke rezistencije na tipranavir, dok je potpuni 10- mutacijski genotip imao 69-struku rezistencijuna tipranavir.
Reverse the cap and use it to twist and remove the seal from the pipette, as shown.
Skinite kapicu i okrenite da probijete membranu kako je prikazano.
reverse transcriptase inhibitor)
inhibitor reverzne transkriptaze)
Reversibility of altered renal function has been observed with supportive treatment and discontinuation of potentially causative agents, including exenatide.
Opažena je reverzibilnost promijenjene bubrežne funkcije nakon uvođenja potpornog liječenja i obustave lijekova koji su je potencijalno mogli uzrokovati, uključujući eksenatid.
Reversibility of the effects on menstrual cycle length was demonstrated.
Pokazalo se da učinci na duljinu menstrualnog ciklusa reverzibilni.
Reversibility of the epithelial tympanic membrane blistering is also likely through epithelial migration, a natural self-cleaning and self–repair mechanism for the tympanic membrane and ear canal.
Reverzibilnost nastanka mjehurića na timpaničkoj membrani se najvjerojatnije događa migracijom epitela, prirodnim mehanizmom samočišćenja i samopopravka timpaničke membrane i ušnog kanala.
Reversible haemolytic reactions have been observed in patients, especially those with blood groups A, B, and AB.
Reverzibilne hemolitičke reakcije su opažene u bolesnika, naročito onih s krvnim grupama A, B i AB.
Reversible haemolytic reactions have been observed in patients, especially those withnon-0 blood groups in immunomodulatory treatment.
Reverzibilne hemolitičke reakcije tijekom imunomodulatornog liječenja opažene su u bolesnika, naročito onih koji nisu krvna grupa 0.
Reversible inflammation at the injection site was noted in all groups (including controls) and was more severe in the 6 and 20 mg/kg dose groups.
Reverzibilna upala na mjestu injekcije zabilježena je u svim skupinama (uključujući i kontrolne) i bila je teža u skupinama koja je primala doze od 6 i 20 mg/kg.
Reversible male infertility.
reverzibilna muška neplodnost;
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [area under the curve] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih s 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
Reversible neutropenia, thrombocytopenia, or anaemiaa developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih s 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
Reversible neutropenia, thrombocytopenia, or anemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih dozom od 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
Reversible posterior leukoencephalopathy syndrome
Sindrom reverzibilne posteriorne leukoencefalopatije
Reversible posterior leukoencephalopathy syndrome (a condition characterised by headache, confusion, seizures and visual loss)
indrom reverzibilne posteriorne leukoencefalopatije (stanje koje obilježavaju glavobolja, smetenost, napadaji i gubitak vida)
Reversible posterior leukoencephalopathy syndrome (RPLS) may occur rarely during treatment with any asparaginase (see section 4.8).
Sindrom reverzibilne posteriorne leukoencefalopatije (RPLS) može se u rijetkim slučajevima pojaviti tijekom liječenja bilo kojom asparaginazom (vidjeti dio 4.8).
Reversible posterior leukoencephalopathy syndrome (RPLS) may occur rarely during treatment with any asparaginase.
Sindrom reverzibilne posteriorne leukoencefalopatije (RPLS) može se u rijetkim slučajevima pojaviti tijekom liječenja bilo kojom asparaginazom.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES) has been observed with cabozantinib.
Prilikom primjene kabozantiniba zabilježen je sindrom reverzibilne posteriorne leukoencefalopatije (RPLS), također poznat kao sindrom posteriorne reverzibilne encefalopatije (PRES).
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES), has been observed with cabozantinib.
Prilikom primjene kabozantiniba zabilježen je sindrom reverzibilne posteriorne leukoencefalopatije (RPLS), također poznat kao sindrom posteriorne reverzibilne encefalopatije (PRES).
Reversible red colouration of the skin and mucous membranes (see above).
Reverzibilna crvena boja kože i sluznica (vidjeti prethodni tekst).
Reversible swelling of the brain (posterior reversible encephalopathy syndrome).
Prolazno oticanje mozga (sindrom posteriorne reverzibilne encefalopatije).
Reversible, minimal injection site reactions were noted in both dose groups.
Reverzibilne, minimalne reakcije na mjestu injekcije uočene su obje skupine doziranja.
Reversible, selective MAO-A inhibitor (moclobemide)
Reverzibilni, selektivni MAO-A inhibitor (moklobemid)
Reversing dabigatran therapy exposes patients to the thrombotic risk of their underlying disease.
Poništenje terapije dabigatranom izlaže bolesnike riziku od tromboze zbog njihove osnovne bolesti ili stanja.
Revestive 5 mg powder and solvent for solution for injection
Revestive 5 mg prašak i otapalo za otopinu za injekciju teduglutid
Revestive 5 mg powder and solvent for solution for injection Teduglutide
Revestive 5 mg prašak i otapalo za otopinu za injekciju teduglutid
Revestive 5 mg powder for solution for injection Teduglutide
Revestive 5 mg prašak za otopinu za injekciju teduglutid
Revestive has not been studied in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Lijek Revestive nije ispitan u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dijelove 4.4 i 5.2).
Revestive has not been studied in patients with severe hepatic impairment.
Revestive nije ispitan u bolesnika s teškim oštećenjem funkcije jetre.
Revestive has not been studied in patients with severe, clinically unstable concomitant diseases, (e.g., cardiovascular, respiratory, renal, infectious, endocrine, hepatic, or CNS), or in patients with malignancies within the last five years (see section 4.3).
Revestive nije ispitan u bolesnika s teškim, klinički nestabilnim pratećim bolestima (npr. kardiovaskularnim, dišnim, bubrežnim, zaraznim, endokrinim, jetrenim ili središnjeg živčanog sustava) ili u bolesnika sa zloćudnim bolestima u posljednjih pet godina (vidjeti dio 4.3).
Revestive is a medicine that contains the active substance teduglutide.
Revestive je lijek koji sadrži djelatnu tvar teduglutid.
Revestive is a powder and solvent for solution for injection (5 mg powder in vial, 0.5 ml solvent in pre-filled syringe).
Revestive je prašak i otapalo za otopinu za injekciju (5 mg praška u bočici, 0,5 ml otapala u napunjenoj štrcaljki).
Revestive is for injection under the skin (subcutaneous injection).
Revestive se ubrizgava pod kožu (supkutana injekcija).
Revestive is given as an injection under the skin of the abdomen.
Revestive se primjenjuje kao supkutana injekcija.
Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome.
Lijek Revestive indiciran je za liječenje bolesnika od navršene 1 godine nadalje sa sindromom kratkog crijeva.
Revestive is injected under the skin (subcutaneously) once daily.
Revestive treba ubrizgati pod kožu (supkutano) jednom dnevno.
Revestive is used after ‘intestinal adaptation’ has occurred (changes in the function of the bowel to compensate for its reduced size following surgery).
Revestive se koristi nakon adaptacije crijeva (promjene funkcije crijeva kako bi se kompenziralo njegovo smanjenje poslije operacije).
Revestive is used to treat adults and children from the age of 1 year with short bowel syndrome.
Revestive se koristi u liječenju odraslih i djece od navršene 1. godine života sa sindromom kratkog crijeva.
Revestive must not be used in patients who have, or are suspected to have, a cancer.
Lijek Revestive ne smije se koristiti ako bolesnici imaju karcinom ili se sumnja da ga imaju.
Revestive should not be used if a cancer is detected during your colonoscopy.
Revestive ne smijete primati ako se kolonoskopijom otkrije rak.
Revestive treatment induced expansion of the absorptive epithelium by significantly increasing villus height in the small intestine.
Liječenje lijekom Revestive potaknulo je povećanje apsorpcijskog epitela značajnim povećanjem visine resica u tankom crijevu.
Revestive was shown to stimulate the growth of cells in the lining of the gut in experimental models.
Dokazano je da lijek Revestive potiče rast stanica u stjenci crijeva kod eksperimentalnih modela.
Revestive was studied in a 12-week, open-label, clinical study in 42 paediatric subjects aged 1 year through 14 years with SBS who were dependent on parenteral nutrition.
Revestive je ispitan u 12-tjednom, otvorenom kliničkom ispitivanju u 42 pedijatrijska ispitanika u dobi od 1 do 14 godina sa SKC-om koji su ovisili o parenteralnoj prehrani.
Revestive was studied in two main studies.
Revestive je ispitan u dva glavna ispitivanja.
Review of the PET reading criteria, including method of image review, criteria for interpretation, and images demonstrating the binary read methodology
Pregled kriterija za interpretaciju PET snimaka, uključujući metodu pregleda snimke, kriterije za interpretaciju i snimke na kojima se može pokazati metodologija binarnog očitavanja
Review of the PET reading criteria, including method of image review, criteria for interpretation, and images demonstrating the binary read methodology.
Pregled kriterija očitavanja PET-a, uključujući metodu pregleda slike, kriterij za tumačenje i slike koje pokazuju ‘binary read’ metodologiju.
Review of the PET reading criteria, including method of image review, criteria for interpretation, and images demonstrating the read methodology;
Pregled kriterija očitavanja nalaza dobivenih PET-om, uključujući i metodu pregleda slika, kriterije za tumačenje i prikaz slika koje objašnjavaju metodologiju tumačenja;
Review the LEMTRADA Patient Guide and Package Leaflet with your patient.
Zajedno s bolesnikom pregledajte Vodič za bolesnike koji se liječe lijekom LEMTRADA i Uputu o lijeku.
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Revinty Ellipta 184 mikrograma/22 mikrograma prašak inhalata flutikazonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 184 mikrograma/22 mikrograma prašak inhalata, dozirani
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate /vilanterol
Revinty Ellipta 184 mikrograma/22 mikrograma prašak inhalata, dozirani flutikazonfuroat/vilanterol
Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 184 mikrograma/22 mikrograma prašak inhalata, dozirani flutikazonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder fluticasone furoate/vilanterol
Revinty Ellipta 92 mikrograma/22 mikrograma prašak inhalata flutikazonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 92 mikrograma/22 mikrograma prašak inhalata, dozirani
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed fluticasone furoate/vilanterol
Revinty Ellipta 92 mikrograma/22 mikrograma prašak inhalata, dozirani flutikazonfuroat/vilanterol
Revinty Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed Revinty Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed
Revinty Ellipta 92 mikrograma/22 mikrograma prašak inhalata, dozirani Revinty Ellipta 184 mikrograma/22 mikrograma prašak inhalata, dozirani
Revinty Ellipta 92/22 microgram (92 micrograms of fluticasone furoate and 22 micrograms of vilanterol) can be used for the
Revinty Ellipta od 92/22 mikrograma (92 mikrograma flutikasonfuroata i 22 mikrograma vilanterola) može se primijeniti za liječenje astme i KOPB-a, dok se Revinty Ellipta od 184/22 mikrograma (184 mikrograma flutikasonfuroata i
Revinty Ellipta contains two active substances.
Revinty Ellipta sadrži dvije djelatne tvari.
Revinty Ellipta is a medicine that contains the active substances fluticasone furoate and vilanterol.
Revinty Ellipta je lijek koji sadrži djelatne tvari flutikazonfuroat i vilanterol.
Revinty Ellipta is a white powder.
Revinty Ellipta je bijeli prašak.
Revinty Ellipta is for inhalation use only.
Revinty Ellipta namijenjen je isključivo za inhalaciju.
Revinty Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.
Revinty Ellipta je indiciran za redovito liječenje astme u odraslih osoba i adolescenata u dobi od 12 i više godina kod kojih je primjerena primjena kombiniranog lijeka (dugodjelujućeg beta2-agonista i inhalacijskog kortikosteroida) : u bolesnika u kojih astma nije dovoljno dobro kontrolirana inhalacijskim kortikosteroidima te kratkodjelujućim inhalacijskim beta2-agonistima koji se primjenjuju 'prema potrebi'.
Revinty Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long- acting beta2-adrenergic agonists.
Revinty Ellipta se ne smije koristiti u kombinaciji s drugim dugodjelujućim agonistima beta2-adrenergičkih receptora niti lijekovima koji sadrže dugodjelujuće beta2-adrenergičke agoniste.
Revinty Ellipta should only be considered for pregnant women if the expected benefits outweigh the risks.
Primjenu lijeka Revinty Ellipta u trudnica treba razmotriti samo ako je očekivana korist veća od mogućeg rizika.
RevitaCAM 5mg/ml oromucosal spray for Dogs
RevitaCAM 5 mg/ml sprej za usnu sluznicu za pse
RevitaCAM is presented in:
pumpica od 100 µl
Revlimid 10 mg hard capsules
Revlimid 10 mg tvrde kapsule
Revlimid 10 mg hard capsules are blue-green/pale yellow, with “REV 10 mg” written on them.
Revlimid 10 mg tvrde kapsule su plavozelene/blijedožute, s oznakom „REV 10 mg“.
Revlimid 10 mg hard capsules lenalidomide
Revlimid 10 mg tvrde kapsule lenalidomid
Revlimid 10 mg hard capsules:
Revlimid 10 mg tvrde kapsule:
Revlimid 15 mg hard capsules
Revlimid 15 mg tvrde kapsule
Revlimid 15 mg hard capsules are pale blue/white, with “REV 15 mg” written on them.
Revlimid 15 mg tvrde kapsule su blijedoplave/bijele, s oznakom „REV 15 mg“.
Revlimid 15 mg hard capsules lenalidomide
Revlimid 15 mg tvrde kapsule lenalidomid
Revlimid 15 mg hard capsules:
Revlimid 15 mg tvrde kapsule:
Revlimid 2.5 mg hard capsules
Revlimid 2,5 mg tvrde kapsule
Revlimid 2.5 mg hard capsules are blue-green/white, with “REV 2.5 mg” written on them.
Revlimid 2,5 mg tvrde kapsule su plavozelene/bijele, s oznakom „REV 2.5 mg“.
Revlimid 2.5 mg hard capsules lenalidomide
Revlimid 2,5 mg tvrde kapsule lenalidomid
Revlimid 2.5 mg hard capsules Revlimid 5 mg hard capsules Revlimid 7.5 mg hard capsules Revlimid 10 mg hard capsules Revlimid 15 mg hard capsules Revlimid 20 mg hard capsules Revlimid 25 mg hard capsules
Revlimid 2,5 mg tvrde kapsule Revlimid 5 mg tvrde kapsule Revlimid 7,5 mg tvrde kapsule Revlimid 10 mg tvrde kapsule Revlimid 15 mg tvrde kapsule Revlimid 20 mg tvrde kapsule Revlimid 25 mg tvrde kapsule
Revlimid 2.5 mg hard capsules:
Revlimid 2,5 mg tvrde kapsule:
Revlimid 20 mg hard capsules
Revlimid 20 mg tvrde kapsule
Revlimid 20 mg hard capsules are blue-green/pale blue, with “REV 20 mg” written on them.
Revlimid 20 mg tvrde kapsule su plavozelene/blijedoplave, s oznakom „REV 20 mg“.
Revlimid 20 mg hard capsules lenalidomide
Revlimid 20 mg tvrde kapsule lenalidomid
Revlimid 20 mg hard capsules:
Revlimid 20 mg tvrde kapsule:
Revlimid 25 mg hard capsules
Revlimid 25 mg tvrde kapsule
Revlimid 25 mg hard capsules arewhite, with “REV 25 mg” written on them.
Revlimid 25 mg tvrde kapsule su bijele, s oznakom „REV 25 mg“.
Revlimid 25 mg hard capsules lenalidomide
Revlimid 25 mg tvrde kapsule lenalidomid
Revlimid 25 mg hard capsules:
Revlimid 25 mg tvrde kapsule:
Revlimid 5 mg hard capsules
Revlimid 5 mg tvrde kapsule
Revlimid 5 mg hard capsules are white, with “REV 5 mg” written on them.
Revlimid 5 mg tvrde kapsule su bijele, s oznakom „REV 5 mg“.
Revlimid 5 mg hard capsules lenalidomide
Revlimid 5 mg tvrde kapsule lenalidomid
Revlimid 5 mg hard capsules:
Revlimid 5 mg tvrde kapsule:
Revlimid 7.5 mg hard capsules
Revlimid 7,5 mg tvrde kapsule
Revlimid 7.5 mg hard capsules are pale yellow/white, with “REV 7.5 mg” written on them.
Revlimid 7,5 mg tvrde kapsule su blijedožute/bijele, s oznakom „REV 7.5 mg“.
Revlimid 7.5 mg hard capsules lenalidomide
Revlimid 7,5 mg tvrde kapsule lenalidomid
Revlimid 7.5 mg hard capsules:
Revlimid 7,5 mg tvrde kapsule:
Revlimid and the medicines you take in combination with Revlimid are taken on certain days over 4 weeks (28 days).
Revlimid i lijekovi koje ćete uzimati u kombinaciji s Revlimidom uzimaju se na određene dane tijekom 4 tjedna (28 dana).
Revlimid can increase the number of healthy red blood cells that the body produces by reducing the number of abnormal cells:
Revlimid može povećati broj zdravih crvenih krvnih stanica koje tijelo stvara tako da smanjuje broj abnormalnih stanica:
Revlimid can stop the signs and symptoms of multiple myeloma getting worse.
Revlimid može zaustaviti pogoršanje znakova i simptoma multiplog mijeloma.
Revlimid capsules contain lactose.
Kapsule Revlimida sadrže laktozu.
Revlimid capsules should be taken at about the same time on the scheduled days.
Kapsule Revlimida treba uzimati otprilike u isto vrijeme svakoga dana predviđenog za uzimanje lijeka.
Revlimid contains lactose
Revlimid sadrži laktozu
Revlimid contains lactose.
Revlimid sadrži laktozu.
Revlimid contains the active substance ‘lenalidomide’.
Revlimid sadrži djelatnu tvar zvanu „lenalidomid“.
Revlimid has been studied in two main studies involving 704 patients with previously treated multiple myeloma.
Revlimid je ispitan u dva glavna ispitivanja koja su obuhvatila 704 bolesnika s prethodno liječenim multiplom mijelomom.
Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Revlimid je, u kombinaciji s deksametazonom, indiciran u liječenju multiplog mijeloma u odraslih bolesnika koji su prethodno primili barem jednu liniju liječenja.
Revlimid in patients newly diagnosed with multiple myeloma
Revlimid u bolesnika s novodijagnosticiranim multiplim mijelomom
Revlimid in patients with multiple myeloma who have had at least one other type of treatment before
Revlimid u bolesnika s multiplim mijelomom koji su prije liječeni barem jednim oblikom liječenja
Revlimid is a cancer medicine that contains the active substance lenalidomide.
Revlimid je lijek protiv karcinoma koji sadrži djelatnu tvar lenalidomid.
Revlimid is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant (see section 4.2).
Revlimid je indiciran za liječenje odraslih bolesnika s prethodno neliječenim multiplim mijelomom (MM) koji nisu prikladni za transplantaciju (vidjeti dio 4.2).
Revlimid is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1).
Revlimid je indiciran za liječenje odraslih bolesnika s relapsom ili refraktornim limfomom plaštenih stanica (engl. mantle cell lymphoma, MCL) (vidjeti dijelove 4.4 i 5.1).
Revlimid is indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Revlimid je indiciran za liječenje bolesnika s anemijom ovisnom o transfuziji zbog mijelodisplastičnih sindroma (MDS) niskog ili srednjeg - 1 rizika, koji su povezani s citogenetskom abnormalnosti koja se očituje kao izolirana delecija 5q, kada su druge terapijske mogućnosti nedovoljne ili neodgovarajuće.
Revlimid is not recommended for use in children and adolescents under 18 years.
Revlimid se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
Revlimid is only used in newly diagnosed patients when you are unable to be treated with a bone marrow transplant.
Revlimid se koristi u bolesnika kojima je tek dijagnosticiran multipli mijelom kada ih se ne može liječiti transplantacijom koštane srži.
Revlimid is taken in repeated 28-day cycles: the patient takes the medicine once a day for 21 days at around the same time each day, followed by seven days off the medicine.
Revlimid se primjenjuje u ponavljajućim 28-dnevnim ciklusima: bolesnik uzima lijek jednom dnevno 21 dan otprilike u isto vrijeme svaki dan, nakon čega slijedi sedam dana bez lijeka.
Revlimid is taken in treatment cycles, each cycle lasting 28 days (see above “Treatment cycle”).
Revlimid se uzima u ciklusima liječenja, a svaki ciklus traje 28 dana (pogledajte prethodni tekst „Ciklus liječenja“).
Revlimid is taken together with an anti-inflammatory medicine called ‘dexamethasone’.
Revlimid se uzima zajedno s protuupalnim lijekom pod nazivom ‘deksametazon’
Revlimid is used alone to treat adult patients who have been diagnosed with myelodysplastic syndromes, when all of the following apply:
Revlimid se koristi za liječenje odraslih bolesnika kojima je dijagnosticiran mijelodisplastični sindrom, ali samo ako su ispunjeni ovi uvjeti:
Revlimid is used alone to treat adult patients who have been diagnosed with previously-treated MCL.
Revlimid se primjenjuje sam za liječenje odraslih bolesnika kojima je dijagnosticiran prethodno liječen limfom plaštenih stanica.
Revlimid is used for the treatment of multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma, which are conditions affecting blood cells and bone marrow.
Revlimid se koristi za liječenje multiplog mijeloma, mijelodisplastičnih sindroma i limfoma plaštenih stanica kao bolesti koje pogađaju krvne stanice i koštanu srž.
Revlimid is used in adults for:
Revlimid se primjenjuje u odraslih za liječenje: